WALTHAM, Mass. (AP) -- Oscient Pharmaceuticals Corp. said Friday it amended a contract for its Factive antibiotic with LG Life Sciences Ltd. to include several European countries to the licensing agreement. The amendment means all nations within the European Union are now included and royalty rates reduced on future sales. The company said the move is aimed at enabling maximum investment in the antibiotic brand through a potential European partnership.
